Ablynx Receives Grant To Accelerate ALX-0061 Programme
Ablynx claimed that ALX-0061 binds to the IL-6 receptor (IL-6R). It has a high potency and demonstrated a favourable pharmacodynamic (PD), pharmacokinetic (PK) and safety profile in pre-clinical
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
In Phase I development of the virus detection system, which utilizes PositiveID’s licensed Receptors’ CARA (Combinatorial Artificial Receptor Array) platform, PositiveID successfully achieved proof-of-concept. CARA support and complementary